and 1 other(s)
Introduction: Insulin pump therapy or continuous subcutaneous insulin infusion (CSII) is known to be one of the most effective methods of treatment of diabetic patients. Unfortunately, some patients decide to discontinue CSII therapy for different reasons. Aim: To evaluate the discontinuation rates of pump therapy in Moscow Region Materials and Methods: Since a high-technology medical care has become available in Russian Federation, diabetic patients got an opportunity to receive an insulin pump therapy. Nevertheless, a compulsory insurance covers only the cost of the insulin pump. Thus, patients still have to buy monthly consumables at their own expense. The data presented were obtained during a routine clinical practice. Patients who were switched on insulin pump therapy in Endocrinology Department of Moscow Regional Research and Clinical Institute were followed-up from 2015 to the present day. The information about the discontinuation of pump therapy was received from patients during personal visits or by phone calls. Results: Data from 274 patients were received. About 30% of patients discontinued CSII therapy during the first 3 months. The rate of discontinuation then decreased, and after the 6 months of CSII only 7% of remained patients stopped this method of treatment. The main reason reported was the high cost of monthly consumables, such as infusion lines, syringes, batteries etc (89% of patients). The other reasons included: not feeling comfortable wearing the device (5%), lack of improvement in control (3%), dermatological problems and needle site abscesses (2%), and total pump failure (1%). Conclusion: Despite the obvious benefits of CSII therapy, patients in Moscow Region discontinue pump therapy mainly because of the cost issues. The data presented in this study prove the necessity of including monthly consumables in the insurance plans.
No datasets are available for this submission.
No license information is available for this submission.